文献速递炎症性肠病

综述文章:外部衍生对照臂——炎症性肠病临床试验的机遇?

Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-21

本文综述了利用外部衍生数据合成对照组或扩充现有对照组的试验设计,并总结了监管机构对使用外部对照进行上市许可的立场。通过无限制的PubMed文献检索,发现外部对照正越来越多地用于炎症性肠病等领域并获得监管认可,但缺乏随机化和盲法易致显著偏倚,需稳健的统计方法平衡组间患者水平数据。

要点

  • 外部对照设计可为早期试验提供疗效评估,避免随机安慰剂对照的招募与伦理挑战。
  • 外部对照缺乏随机化和盲法,存在显著偏倚风险,需稳健统计方法确保组间平衡。
  • 该设计尚不能替代传统随机安慰剂对照试验,但可能以更少患者、更快速度和更低成本提供折中方案。

核心结论

  • 外部对照方法虽有若干缺陷且不足以替代传统随机安慰剂对照试验,但可能提供一种折中方案,以更快的速度、更少的患者和更低的成本解决关键研究问题。

研究设计与样本

  • 采用无限制的PubMed文献检索,检索词包括「外部对照」和「历史对照」等,以识别相关文章。

主要发现

  • 外部对照正越来越多地用于癌症和罕见病之外的领域,包括炎症性肠病,并日益获得监管机构认可。
  • 此类设计尤其在早期试验中可提供药物开发关键节点的信息,并允许评估干预措施疗效,而无需应对所述的伦理和入组数量挑战。
  • 缺乏随机化和盲法使此类设计易受显著偏倚影响。
  • 各研究组需要稳健的统计和计算方法,以确保组间患者水平数据充分平衡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 缺乏随机化和盲法使此类设计易受显著偏倚影响。
  • 该方法的稳健性不足以替代传统随机、安慰剂对照试验。
  • 各研究组需要稳健的统计和计算方法以确保患者水平数据充分平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the greatest challenges in the current IBD clinical trial landscape is, perhaps, the recruitment and retention of eligible participants. Seamless testing of promising investigational compounds is paramount to address unmet needs, but this is hindered by a number of barriers, particularly patient concerns of placebo assignment. AIMS: To review the use of novel trial designs leveraging externally derived data to synthetically create control groups or augment existing ones, and to summarise the regulatory position on the use of external controls for market authorisation. METHODS: We conducted a PubMed literature search without restriction using search terms such as 'external controls' and 'historical controls' to identify relevant articles. RESULTS: External controls are increasingly being used outside the context of cancer and rare diseases, including IBD, and increasingly recognised by regulatory bodies. Such designs, particularly in earlier phase trials, can inform key nodes in drug development and permit evaluating efficacy of interventions without combating the ethical and numerical enrolment challenges described. However, the lack of randomisation and blinding subjects them to significant bias. Groups require robust statistical and computational approaches to ensure patient-level data across groups are adequately balanced. CONCLUSIONS: While this approach has several pitfalls, and is not robust enough to replace traditional randomised, placebo-controlled trials, it may offer a compromise to address key research questions at a more rapid pace, with fewer patients, and lower cost.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Honap S, Peyrin-Biroulet L. Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease? Aliment Pharmacol Ther. 2023. PMID: 37602530. doi:10.1111/apt.17684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。